Additionally, concerns have been raised regarding increased thromboembolic complications, particularly those affecting the arterial circulation, associated with the use of factor VIIa.
Although factor VIIa is likely safe among patients with MBL, it is unlikely to be beneficial and therefore its use in DCR cannot be recommended.